Pliant Therapeutics (PLRX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

PLRX Stock Forecast

Pliant Therapeutics stock forecast is as follows: an average price target of $35.50 (represents a 168.94% upside from PLRX’s last price of $13.20) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

PLRX Price Target

The average price target for Pliant Therapeutics (PLRX) is $35.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $33.00. This represents a potential 168.94% upside from PLRX's last price of $13.20.

PLRX Analyst Ratings

Buy

According to 5 Wall Street analysts, Pliant Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PLRX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Pliant Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 13, 2024	Ed Arce	H.C. Wainwright	$38.00	$11.84	220.95%	187.88%
Sep 09, 2024	Faisal Khurshid	Leerink Partners	$33.00	$12.87	156.41%	150.00%
May 23, 2024	Yasmeen Rahimi	Piper Sandler	$40.00	$13.85	188.81%	203.03%
May 07, 2024	Alex Thompson	Stifel Nicolaus	$32.00	$13.91	130.05%	142.42%
May 07, 2024	Jeff Jones	Oppenheimer	$48.00	$13.79	248.08%	263.64%
May 07, 2024	Ed Arce	H.C. Wainwright	$36.00	$13.79	161.06%	172.73%
May 07, 2024	Brian Abrahams	RBC Capital	$45.00	$13.79	226.32%	240.91%
Dec 07, 2022		J.P. Morgan	$42.00	$17.18	144.47%	218.18%

The latest Pliant Therapeutics stock forecast, released on Sep 13, 2024 by Ed Arce from H.C. Wainwright, set a price target of $38.00, which represents a 220.95% increase from the stock price at the time of the forecast ($11.84), and a 187.88% increase from PLRX last price ($13.20).

Pliant Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	7
Avg Price Target	-	-	$38.86
Last Closing Price	$13.20	$13.20	$13.20
Upside/Downside	-100.00%	-100.00%	194.39%

In the current month, the average price target of Pliant Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pliant Therapeutics's last price of $13.20. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 17, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 13, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 09, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 06, 2024	Citigroup	Buy	Buy	Hold
May 23, 2024	Piper Sandler	Overweight	Overweight	Hold
May 07, 2024	Oppenheimer	Outperform	Outperform	Hold
May 07, 2024	H.C. Wainwright	Buy	Buy	Hold
May 07, 2024	RBC Capital	Outperform	Outperform	Hold
May 07, 2024	Citigroup	Buy	Buy	Hold
Mar 01, 2022	RBC Capital	Outperform	Outperform	Hold

Pliant Therapeutics's last stock rating was published by Piper Sandler on Sep 17, 2024. The company gave PLRX a "Overweight" rating, the same as its previous rate.

Pliant Therapeutics Financial Forecast

Pliant Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$4.84M	-	$248.00K	$1.33M	$1.97M	$1.48M	$4.99M	$1.25M	$2.00M	$1.61M	$1.79M	$2.17M	$4.46M	$4.81M	$3.60M
Avg Forecast	-	-	-	-	$250.00K	$250.00K	$250.00K	$250.00K	$125.00K	$472.22K	$732.50K	$580.63K	$814.11K	$1.02M	$1.21M	$1.39M	$1.45M	$1.79M	$1.35M	$1.26M	$3.00M	$3.17M	$4.17M	$4.23M	$3.37M	$2.50M	$3.70M
High Forecast	-	-	-	-	$250.00K	$250.00K	$250.00K	$250.00K	$125.00K	$472.33K	$732.75K	$580.81K	$814.11K	$1.02M	$1.21M	$1.39M	$1.45M	$1.79M	$1.35M	$1.26M	$3.00M	$3.17M	$4.17M	$4.23M	$3.37M	$2.50M	$3.70M
Low Forecast	-	-	-	-	$250.00K	$250.00K	$250.00K	$250.00K	$125.00K	$472.11K	$732.25K	$580.44K	$814.11K	$1.02M	$1.21M	$1.39M	$1.45M	$1.79M	$1.35M	$1.26M	$3.00M	$3.17M	$4.17M	$4.23M	$3.37M	$2.50M	$3.70M
# Analysts	-	-	-	-	1	1	1	3	12	6	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	5.95%	-	0.20%	0.96%	1.35%	0.83%	3.70%	0.99%	0.67%	0.51%	0.43%	0.51%	1.33%	1.93%	0.97%

Pliant Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $580.63K, with a low forecast of $580.44K, and a high forecast of $580.81K. PLRX's average Quarter revenue forecast represents a -88.00% decrease compared to the company's last Quarter revenue of $4.84M (Dec 23).

Pliant Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	1	1	1	3	12	6	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-46.57M	$-47.69M	$-47.33M	$-36.78M	$-34.74M	$-31.49M	$-29.18M	$-27.76M	$-23.84M	$-26.66M	$-22.46M	$-22.50M	$-18.68M	$-16.20M	$-16.68M
Avg Forecast	-	-	-	-	$-198.33K	$-198.33K	$-198.33K	$-198.33K	$-99.17K	$-374.63K	$-581.11K	$-42.30M	$-645.86K	$-811.91K	$-961.91K	$-33.44M	$-24.64M	$-1.43M	$-1.08M	$-26.43M	$-2.40M	$-2.53M	$-3.33M	$-21.00M	$-2.69M	$-2.00M	$-10.30M
High Forecast	-	-	-	-	$-198.33K	$-198.33K	$-198.33K	$-198.33K	$-99.17K	$-374.54K	$-580.91K	$-33.84M	$-645.86K	$-811.91K	$-961.91K	$-26.75M	$-19.71M	$-1.43M	$-1.08M	$-21.15M	$-2.40M	$-2.53M	$-3.33M	$-16.80M	$-2.69M	$-2.00M	$-8.24M
Low Forecast	-	-	-	-	$-198.33K	$-198.33K	$-198.33K	$-198.33K	$-99.17K	$-374.71K	$-581.31K	$-50.76M	$-645.86K	$-811.91K	$-961.91K	$-40.12M	$-29.57M	$-1.43M	$-1.08M	$-31.72M	$-2.40M	$-2.53M	$-3.33M	$-25.20M	$-2.69M	$-2.00M	$-12.36M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	72.11%	58.73%	49.20%	1.10%	1.41%	21.97%	27.04%	1.05%	9.94%	10.53%	6.74%	1.07%	6.94%	8.11%	1.62%

undefined analysts predict PLRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pliant Therapeutics's previous annual EBITDA (undefined) of $NaN.

Pliant Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	1	1	1	3	12	6	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-41.11M	$-41.49M	$-41.19M	$-28.14M	$-34.60M	$-27.95M	$-29.35M	$-27.88M	$-24.80M	$-27.05M	$-22.83M	$-22.86M	$-19.03M	$-16.53M	$-17.00M
Avg Forecast	$-60.12M	$-61.95M	$-61.95M	$-61.95M	$-65.68M	$-63.68M	$-61.95M	$-60.38M	$-60.02M	$-58.86M	$-51.53M	$-43.17M	$-49.41M	$-47.08M	$-43.32M	$-34.12M	$-25.35M	$-44.75M	$-49.05M	$-26.98M	$-45.93M	$-41.69M	$-40.47M	$-21.33M	$-43.02M	$-51.24M	$-10.49M
High Forecast	$-60.12M	$-61.95M	$-61.95M	$-61.95M	$-65.68M	$-63.68M	$-61.95M	$-54.09M	$-49.28M	$-58.86M	$-51.53M	$-34.53M	$-45.45M	$-47.08M	$-43.32M	$-27.30M	$-20.28M	$-44.75M	$-49.05M	$-21.58M	$-45.93M	$-41.69M	$-40.47M	$-17.07M	$-43.02M	$-51.24M	$-8.40M
Low Forecast	$-60.12M	$-61.95M	$-61.95M	$-61.95M	$-65.68M	$-63.68M	$-61.95M	$-63.53M	$-64.44M	$-58.86M	$-51.53M	$-51.80M	$-61.26M	$-47.08M	$-43.32M	$-40.95M	$-30.42M	$-44.75M	$-49.05M	$-32.37M	$-45.93M	$-41.69M	$-40.47M	$-25.60M	$-43.02M	$-51.24M	$-12.59M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.83%	0.88%	0.95%	0.82%	1.37%	0.62%	0.60%	1.03%	0.54%	0.65%	0.56%	1.07%	0.44%	0.32%	1.62%

Pliant Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PLRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Pliant Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	1	1	1	3	12	6	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$13.85M	$15.35M	$14.57M	$14.15M	$14.25M	$8.82M	$8.30M	$8.58M	$-47.27M	$7.67M	$5.47M	$6.57M	$5.63M	$4.59M	$3.04M
Avg Forecast	-	-	-	-	$2.25M	$2.25M	$2.25M	$2.25M	$1.13M	$4.25M	$6.60M	$5.23M	$7.33M	$9.22M	$10.92M	$12.50M	$-48.85M	$16.14M	$12.16M	$11.35M	$27.02M	$28.52M	$37.53M	$38.13M	$30.32M	$22.52M	$1.88M
High Forecast	-	-	-	-	$2.25M	$2.25M	$2.25M	$2.25M	$1.13M	$4.25M	$6.60M	$5.23M	$7.33M	$9.22M	$10.92M	$12.50M	$-39.08M	$16.14M	$12.16M	$11.35M	$27.02M	$28.52M	$37.53M	$38.13M	$30.32M	$22.52M	$2.25M
Low Forecast	-	-	-	-	$2.25M	$2.25M	$2.25M	$2.25M	$1.13M	$4.25M	$6.59M	$5.23M	$7.33M	$9.22M	$10.92M	$12.50M	$-58.62M	$16.14M	$12.16M	$11.35M	$27.02M	$28.52M	$37.53M	$38.13M	$30.32M	$22.52M	$1.50M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.89%	1.66%	1.33%	1.13%	-0.29%	0.55%	0.68%	0.76%	-1.75%	0.27%	0.15%	0.17%	0.19%	0.20%	1.62%

Pliant Therapeutics's average Quarter SG&A projection for Mar 24 is $5.23M, based on 3 Wall Street analysts, with a range of $5.23M to $5.23M. The forecast indicates a -62.25% fall compared to PLRX last annual SG&A of $13.85M (Dec 23).

Pliant Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	1	1	1	3	12	6	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.69	$-0.70	$-0.00	$-0.50	$-0.71	$-0.60	$-0.81	$-0.77	$-0.69	$-0.75	$-0.64	$-0.64	$-0.54	$-0.47	$-1.39
Avg Forecast	$-0.99	$-1.02	$-1.02	$-1.02	$-1.08	$-1.05	$-1.02	$-0.99	$-0.99	$-0.97	$-0.85	$-0.77	$-0.81	$-0.78	$-0.71	$-0.67	$-0.70	$-0.74	$-0.81	$-0.75	$-0.76	$-0.69	$-0.67	$-0.60	$-0.71	$-0.85	$-0.86
High Forecast	$-0.99	$-1.02	$-1.02	$-1.02	$-1.08	$-1.05	$-1.02	$-0.89	$-0.81	$-0.97	$-0.85	$-0.77	$-0.75	$-0.78	$-0.71	$-0.67	$-0.70	$-0.74	$-0.81	$-0.75	$-0.76	$-0.69	$-0.67	$-0.60	$-0.71	$-0.85	$-0.86
Low Forecast	$-0.99	$-1.02	$-1.02	$-1.02	$-1.08	$-1.05	$-1.02	$-1.05	$-1.06	$-0.97	$-0.85	$-0.77	$-1.01	$-0.78	$-0.71	$-0.67	$-0.70	$-0.74	$-0.81	$-0.75	$-0.76	$-0.69	$-0.67	$-0.60	$-0.71	$-0.85	$-0.86
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.85%	0.90%	0.00%	0.75%	1.01%	0.81%	1.00%	1.03%	0.91%	1.09%	0.95%	1.06%	0.76%	0.55%	1.62%

According to undefined Wall Street analysts, Pliant Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PLRX previous annual EPS of $NaN (undefined).

Pliant Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
ARVN	Arvinas	$19.10	$58.50	206.28%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
CYTK	Cytokinetics	$47.78	$90.00	88.36%	Buy
DYN	Dyne Therapeutics	$26.16	$49.00	87.31%	Buy
ETNB	89bio	$7.98	$12.00	50.38%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy
VRDN	Viridian Therapeutics	$20.82	$22.75	9.27%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy

PLRX Forecast FAQ

Is Pliant Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Pliant Therapeutics (PLRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of PLRX's total ratings.

What is PLRX's price target?

Pliant Therapeutics (PLRX) average price target is $35.5 with a range of $33 to $38, implying a 168.94% from its last price of $13.2. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pliant Therapeutics stock go up soon?

According to Wall Street analysts' prediction for PLRX stock, the company can go up by 168.94% (from the last price of $13.2 to the average price target of $35.5), up by 187.88% based on the highest stock price target, and up by 150.00% based on the lowest stock price target.

Can Pliant Therapeutics stock reach $20?

PLRX's average twelve months analyst stock price target of $35.5 supports the claim that Pliant Therapeutics can reach $20 in the near future.

What are Pliant Therapeutics's analysts' financial forecasts?

Pliant Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1M (high $1M, low $1M), average EBITDA is $-793K (high $-793K, low $-793K), average net income is $-252M (high $-245M, low $-255M), average SG&A $9.01M (high $9.01M, low $9.01M), and average EPS is $-4.144 (high $-4.041, low $-4.196). PLRX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-246M (high $-246M, low $-246M), average SG&A $0 (high $0, low $0), and average EPS is $-4.05 (high $-4.05, low $-4.05).

Did the PLRX's actual financial results beat the analysts' financial forecasts?

Based on Pliant Therapeutics's last annual report (Dec 2023), the company's revenue was $1.58M, which missed the average analysts forecast of $4.44M by -64.40%. Apple's EBITDA was $-182M, beating the average prediction of $-35.857M by 408.42%. The company's net income was $-161M, missing the average estimation of $-174M by -7.24%. Apple's SG&A was $57.93M, beating the average forecast of $39.97M by 44.93%. Lastly, the company's EPS was $-2.75, missing the average prediction of $-2.97 by -7.42%. In terms of the last quarterly report (Dec 2023), Pliant Therapeutics's revenue was $4.84M, beating the average analysts' forecast of $814.11K by 494.51%. The company's EBITDA was $-46.573M, beating the average prediction of $-646K by 7111.04%. Pliant Therapeutics's net income was $-41.109M, missing the average estimation of $-49.406M by -16.79%. The company's SG&A was $13.85M, beating the average forecast of $7.33M by 88.95%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-0.814 by -15.18%